67828-69-7

Basic information

• Product Name: methyl 5-chloro-4-hydroxysalicylate
• Synonyms: methyl 5-chloro-4-hydroxysalicylate;2,4-Dihydroxy-5-chlorobenzoic acid methyl ester;5-Chloro-2,4-dihydroxybenzoic acid methyl ester;Benzoic acid, 5-chloro-2,4-dihydroxy-, methyl ester;Einecs 267-287-4;Methyl 3-chloro-4,6-dihydroxybenzoate
• CAS NO: 67828-69-7
• Molecular Formula: C₈H₇ClO₄
• Molecular Weight: 202.59178
• EINECS: 267-287-4
• Mol File: 67828-69-7.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 373.9°Cat760mmHg
• Flash Point: 180°C
• Appearance: /
• Density: 1.488g/cm³
• Vapor Pressure: 4.02E-06mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: methyl 5-chloro-4-hydroxysalicylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-chloro-4-hydroxysalicylate(67828-69-7)
• EPA Substance Registry System: methyl 5-chloro-4-hydroxysalicylate(67828-69-7)

Safety Data

• Hazardous Substances Data: 67828-69-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H7ClO4/c1-13-8(12)4-2-5(9)7(11)3-6(4)10/h2-3,10-11H,1H3

Upstream product

• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 89-86-1 4-hydroxysalicylic acid 
• 171826-80-5 methyl 5-chloro-2-hydroxy-4-methoxybenzoate 
• 67828-44-8 5-chloro-2,4-dihydroxy-benzoic acid 

Downstream Products

• 99854-30-5 5-chloro-2,4-dihydroxy-3-propionyl-benzoic acid methyl ester 
• 100710-07-4 5-chloro-2,4-bis-propionyloxy-benzoic acid methyl ester 
• 1003567-14-3 4-(1-tert-butoxycarbonyl-1-methylethoxy)-5-chloro-2-hydroxybenzoic acid methyl ester 
• 585-07-9 tert-Butyl methacrylate 
• 104851-85-6 3-butyryl-5-chloro-2,4-dihydroxy-benzoic acid methyl ester 
• 644972-73-6 5-fluoro-2-{[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride 

Relevant articles and documents

Crystal form of hepatitis B surface antigen inhibitor and application thereof

The invention discloses a crystal form of a hepatitis B surface antigen inhibitor and a preparation method of the crystal form. The invention further discloses application of the crystal form in preparation of the hepatitis B surface antigen inhibitor.

NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF

The present invention relates to a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof, and a medicinal use thereof, and composition comprising a dihydroxyphenyl compound or a benzamide compound, which is a novel compound having the HSP90 inhibitory activity of the present invention can effectively inhibit HSP90, and thus can be usefully used as a pharmaceutical composition for preventing or treating HSP90-mediated diseases or a health functional food for preventing or improving HSP90-mediated diseases, which selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections.

Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors

Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone that is responsible for the stabilization and maturation of many oncogenic proteins. Therefore, Hsp90 has emerged as an attractive target in the field of cancer chemotherapy. In this study, we report the design, synthesis, and biological evaluation of a series of Hsp90 inhibitors. In particular, compound 30f shows a significant Hsp90α inhibitory activity with IC50 value of 5.3 nM and an excellent growth inhibition with GI50 value of 0.42 μM against non-small cell lung cancer cells, H1975. Compound 30f effectively reduces the expression levels of Hsp90 client proteins including Her2, EGFR, Met, Akt, and c-Raf. Consequently, compound 30f promotes substantial cleavages of PARP, Caspase 3, and Caspase 8, indicating that 30f induces cancer cell death via apoptotic pathway. Moreover, cytochrome P450 assay indicates that compound 30f has weak inhibitory effect on the activities of five major P450 isoforms (IC50 > 5 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clinical interactions between 30f and the substrate drugs of the five major P450 isoforms are not expected. Compound 30f also inhibits the tumor growth in a mouse xenograft model bearing subcutaneous H1975 without noticeable abnormal behavior and body weight changes. The immunostaining and western immunoblot analysis of EGFR, Met, Akt in xenograft tissue sections of tumor further demonstrate a good agreement with the in vitro results.